




The Intellectual Property Engine for Drug Discovery



Press Release

BioLeap to Work with Lycera Corp. on the Discovery of Small-molecules for the Treatment of Patients with Autoimmune Diseases.

New Hope, PA: August 3, 2009 – BioLeap today announced that it has entered into a discovery program with Lycera Corp., a pharmaceutical company headquartered in Ann Arbor, Michigan. BioLeap will use its proprietary fragment-based design technology to design novel small-molecule lead scaffolds for Lycera.

Commenting on the collaboration, David Pompliano, PhD, CEO of BioLeap said, “We are very pleased to be working with Lycera to accelerate the discovery of truly novel anti-inflammatory medicines. BioLeap's platform can sample practically infinite chemical diversity in designing the best next compound to make, minimizing unproductive chemical guesswork and getting to a better drug candidate in a shorter period of time.”

Gary D. Glick, PhD, Founder and CSO of Lycera said, “BioLeap’s record of delivering high value chemical matter to their clients is truly impressive. We are delighted to have them integrated into our drug discovery and development activities”.

About Lycera Corp.

Lycera Corp. is focused on the discovery and development of small-molecule immunomodulators for the treatment of patients with autoimmune diseases including psoriasis, rheumatoid arthritis, lupus erythematosus, inflammatory bowel disease and transplant rejection. Lycera is developing drug candidates that target two novel therapeutic pathways and have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents.

About BioLeap

BioLeap is a leader in computational fragment-based drug design. The company’s proprietary design technology and process successfully addresses one of the biggest problems in pre-clinical drug discovery: the limitation of drug like and patentable leads for important biological targets. BioLeap is using its completely “in-silico” platform to quickly and accurately predict fragment-protein binding information that provides drug designers new insights that enable them to efficiently create new and improved drug molecule candidates. The BioLeap computational approach addresses the time, cost, and low probability of success limitations imposed by traditional library screening and lead optimization methods. BioLeap is utilizing its capabilities to advance its own internal preclinical stage programs while collaboratively enabling non-competing programs with numerous pharmaceutical partners.

Contact:

For BioLeap, LLC
Gerry Evans, Co-founder
215-371-2874
ghe@bioleap.com

For Lycera, Corp.
Gary D. Glick, Founder and CSO
734-233-3061
gary@lycera.com

346A Lurgan Road
New Hope, PA 18938

215-371-2874 / info@bioleap.com / www.bioleap.com